Download 16th Annual St. Jude/PIDS Pediatric Infectious Diseases Research

16th Annual St. Jude/PIDS
Pediatric Infectious Diseases Research Conference
St. Jude Children’s Research Hospital
March 10-11, 2017
Memphis, Tennessee
St. Jude Children’s Research Hospital
Department of Infectious Diseases
262 Danny Thomas Place, Mailstop 320
Memphis, TN 38105-3678
Pediatric Infectious Diseases Society
1300 Wilson Boulevard
Suite 300
Arlington, VA 22209
St. Jude – PIDS Pediatric Infectious Diseases Research Conference
ii
March 3, 2017
Dear Colleagues:
On behalf of St. Jude Children’s Research Hospital and the Pediatric Infectious
Diseases Society, we welcome you to Memphis, Tennessee and the 16th Annual St.
Jude/PIDS Pediatric Infectious Diseases Research Conference!
This year, nearly 200 faculty, fellows, and students will attend the meeting. The
program features a “Frontiers in Infectious Diseases” symposium, with
presentations from leading investigators in infectious diseases and microbiology.
In addition, a series of career development workshops will be available, including
sessions on career paths in global health, industry, clinical research and education.
Perhaps most important, attendees will have an opportunity to present their original
research to colleagues in pediatric infectious diseases, with over 40 abstract
publications in basic science, clinical science, epidemiology, and health outcomes.
We look forward to an excellent meeting and to meeting each of you over the next
few days.
Sincerely,
Elaine I. Tuomanen, MD, FPIDS
Chair, Department of Infectious Diseases
St. Jude Children’s Research Hospital
Buddy Creech, MD, MPH, FPIDS
Chair, Research Affairs Committee
Pediatric Infectious Diseases Society
Research Affairs Committee
Anne Blaschke, MD, PhD
Betsy Herold, MD, FPIDS
Scott James, MD
Damian Krysan, MD, PhD
Miriam Laufer, MD
Elisa Margolis, MD, PharmD
Ian Michelow, MD
William Muller, MD, PhD, FPIDS
Sallie Permar, MD, PhD
Octavio Ramilo, MD, FPIDS
David Rosen, MD, PhD
Jessica Snowden, MD
Paul Spearman, MD, FPIDS
Stephen Spector, MD
Joshua Wolf, MBBS
St. Jude – PIDS Pediatric Infectious Diseases Research Conference
iii
PROGRAM AT A GLANCE
Wednesday, March 8
6:00 – 8:00 PM
Friday, March 10
7:30 AM
8:15 AM
8:30 AM
9:15 AM
10:00 AM
10:30 AM
11:30 AM
12:30
1:30 – 2:15 PM
Satellite Registration
Westin Memphis Beale Street Hotel - Tennessee Ballroom
Marlo Thomas Center for Global Education and Collaboration (GECC)
Breakfast
Welcome and Announcements
Elaine Tuomanen, MD
Buddy Creech, MD, MPH
Keynote Address
The impact of praziquantel given at 12-16 weeks gestation on pregnancy outcomes:
results of a double blind, placebo controlled trial
Jennifer Friedman, MD, PhD
Frontier Lectures in Infectious Diseases
Congenital zika virus infections in macaque monkeys
David O’Connor, PhD
BREAK
Using science to defeat malaria in sub-Saharan Africa
Miriam Laufer, MD
2017 John H. Erskine Lecture in Infectious Diseases
st
Understanding measles in the 21 century
Diane E. Griffin, MD, PhD
Lunch
Oral Abstract Presentations
Clinical and molecular evidence to support school-based mass treatment of malaria
Lauren Cohee, MD
Regulation of IFN and cytosolic DNA responses by autophagy
Anthony Orvedahl, MD, PhD
2:15 PM
2:30 PM
One size does not fit all: evaluating decision support tools for resource limited settings
Sheena Mukkada, MD
BREAK
Differentiating zika and dengue virus infections with a linear peptide array
Emma Mohr, MD, PhD
IFN-α induces RSV-specific IgA production in neonatal mice after RSV infection
Diego Hijano, MD
Investigation of viral virulence determinants of invasive neonatal HSV disease
Lisa Akhtar, MD
Gut microbiome predicts infectious complications in children with acute lymphoblastic
leukemia
Hana Hakim, MD
4:15 – 5:15 PM
6:30 PM
Saturday, March 11
7:30 AM
8:00 AM
Germinating spores as precursors of quiescent cryptococcal infection in the zebrafish
J. Muse Davis, MD, PhD
Poster Presentations
St. Jude/PIDS Reception and Dinner
Itta Bena Restaurant on Beale Street
Marlo Thomas Center for Global Education and Collaboration (GECC)
Breakfast
Luminary in Pediatric Infectious Diseases
Pertussis vaccines: opportunities & challenges
Kathryn M. Edwards, MD
8:45 AM
9:30 AM
10:15 AM
10:30 AM
11:15 AM
12:00 PM
12:30 PM
Frontier Lectures in Infectious Diseases
Change the world: 16 years of molecular, translational, and clinical advances against
fungi and where we are going now
William Steinbach, MD
The human microbiome during pregnancy and its possible role in premature labor
David A. Relman, MD
BREAK
Career Development Presentations
Mentorship: thriving in your mentor/trainee relationship
Kathryn M. Edwards, MD
Career Pathways Brief Talks
Global Health: Miriam Laufer, MD
Industry: William LaVia, MD
Clinician-Educator: Angela Myers, MD, PhD
Clinical Research: William Steinbach, MD
Career Panel Discussion
Lunch and Career Paths Breakout Discussions
K Awards/Loan Repayment Program
Jessica Snowden, MD and Scott James, MD
Staying academic in a clinically-based career
Angela Myers, MD, MPH
2:00 PM
3:00 PM
Mock study section for grant review
John Williams, MD; Betsy Herold, MD; Buddy Creech, MD, MPH; and Elaine Tuomanen,
MD
Research in the Global Health Setting
Point of care clinical decision: resources and opportunities for developing countries—
Charles Russell, PhD
Global Research Panel Discussion
Applying for grants and finding funding for global research projects – Stephen White,
DPhil (Moderator), Hassan Zaraket, PhD and John P. DeVincenzo, MD
Table of Contents
Welcome Letter .................................................................................................................................................... iii
Program at a Glance ............................................................................................................................................ iv
General Information ..............................................................................................................................................1
Continuing Medical Education Information .......................................................................................................3
Presentation Summaries ........................................................................................................................................4
Invited Speakers/Oral Presenters
Poster Presentations.............................................................................................................................................11
Attendee Listing ...................................................................................................................................................13
Map of St. Jude Children’s Research Hospital ................................................................................ Back Cover
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
General Information
Location of Conference
Marlo Thomas Center for Global Education
and Collaboration (GEC)
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Headquarter Hotel Information
Westin Memphis Beale Street Hotel
170 Lt. George W. Lee Avenue
Memphis, TN 38103
(901) 334-5900
Registration Hours – Marlo Thomas Center for Global Education and Collaboration – St. Jude Children’s Research
Hospital campus
Wednesday, March 8:
6:00 – 8:00 pm (Satellite/Wine Reception – Tennessee Ballroom at the Westin Hotel)
Friday, March 10:
7:30 a.m. – 5:30 p.m.
Saturday, March 11:
7:30 a.m. – 4:00 p.m.
Poster Session
The Poster Session will take place on Friday, March 10, from 4:15 to 5:15 p.m. in the foyer of the GEC building.
Travel Stipend Information
Recipients of travel stipends must check in at the registration desk each day to verify attendance. Checks can be picked up at
the registration desk on the last day of the conference.
Mothers’ Room
St. Jude Children’s Research Hospital offers several Mothers’ Rooms around the campus for conference registrants. These
rooms can be used to breastfeed your infant or to express and store milk while at the conference. The closest rooms to use
during conference hours are the Mothers’ Room located at the Chili’s Care Center and Danny Thomas Research Center.
Please seek staff assistance at the Registration Desk before attempting to use this facility.
Shuttle Bus Service
Shuttle bus service is available for registrants to St. Jude Children’s Research Hospital from the Westin Memphis Beale
Street Hotel. Registrants are responsible for providing their own transportation to any other destination while in Memphis.
The following shuttle schedule will be posted at the registration desk. We encourage all attendees taking the shuttle to
take earlier buses on Friday.
Date
Time
Pick-up Site
Friday, March 10
7:00, 7:20 and 7:40 a.m.
Westin Memphis Beale Street Hotel St. Jude
5:15 and 5:30 p.m.
St. Jude
Westin Memphis Beale Street Hotel
5:45 p.m.
St. Jude
Itta Bena Restaurant
8:30 p.m.
Itta Bena Restaurant
St. Jude
7:15 and 7:45 a.m.
Westin Memphis Beale Street Hotel St. Jude
4:15 p.m.
St. Jude
Westin Memphis Beale Street Hotel
4:15 p.m.
St. Jude
Airport
Saturday, March 11
Destination
Friday Night Event
There will be a cocktail reception and dinner Itta Bena Restaurant on Friday, March 10. The restaurant is located 145
Beale Street (above BB King’s Restaurant) and is within walking distance from the Westin Memphis Beale Street Hotel. The
cocktail reception starts at 6 p.m. with dinner starting at 6:30 p.m. Roundtrip shuttle bus services will be provided from St.
Jude only. The buses will depart from St. Jude at 5:45 p.m. and return at 8:45 p.m.
Internet Access
St. Jude Children’s Research Hospital offers wireless Internet access through HopeNet.
Staff Contact Information
For onsite assistance, please contact Christy Phillips (202) 306-9545.
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 1
Continuing Medical Education Information
Educational Objectives
After attending this educational conference, you should be able to:
• Describe original research related to childhood infections
• Explain different career development paths for fellows and junior faculty in pediatric infectious diseases
Please note that session objectives will be presented during the conference as appropriate.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation
requirements and policies of the Accreditation Council for Continuing Medical Education
(ACCME) through the joint providership of St. Jude Children’s Research Hospital and the
Pediatric Infectious Diseases Society. St. Jude Children’s Research Hospital is accredited
by the ACCME to provide continuing medical education for physicians.
Credit Designation
St. Jude Children’s Research Hospital designates this live activity for a maximum of 13.75 AMA PRA
Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their
participation in the activity.
Acknowledgement
Please see the CME Addendum for information regarding commercial support of this activity.
Claiming Credit
To claim AMA PRA Category 1CreditTM or attendance credit for this activity, you must attend the
sessions and follow the instructions below:
• Go to www.stjude.org/cme-certificate
• Enter the email address you used when registering for this conference and your password (if you do not
remember your password or have not previously used this system, follow the instructions)
• Enter the CME activity code 34554
• Choose the appropriate type of credit and enter the amount of time you spent at the conference (maximum
13.75 hours) to claim your credit (note that you will need to input a leading zero for credits < 10, eg,
05.00 for 5 credits)
• Print and/or save your certificate
If you have questions about claiming your CME or attendance certificate, please contact us at
[email protected]. If you registered after February 28, 2017, or onsite, it may take 48 hours to have your
information added to the CME system so that you may claim credit.
Evaluation
A link to the evaluation will be emailed to you after the conference. Your feedback is valuable to us, so
please complete the evaluation.
Disclosure of Financial Relationships
All individuals in a position to control the content of this CME activity (such as faculty, presenters, and
planners) were asked to complete a statement regarding all relevant financial relationships between
themselves or their spouse/partner and any commercial interest (defined by the ACCME as “any entity
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 2
producing, marketing, re-selling, or distributing health care goods and services consumed by, or used on,
patients”). St. Jude CME has reviewed and resolved any conflicts of interest that were identified.
All relevant relationships are disclosed on the CME Addendum; no other speakers, planners, or other
individuals with control over content have disclosed relevant financial relationships with commercial
interests for themselves or their spouse/partner.
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 3
Session 1. Keynote Address
Friday, 8:30 – 9:15 a.m.
GEC Auditorium
The impact of praziquantel given at 12-16 weeks gestation on pregnancy outcomes: results of a double
blind, placebo controlled trial
JENNIFER FRIEDMAN, Brown University, Providence, Rhode Island
An estimated 40 million women of reproductive age are at risk of infection with schistosomiasis. Praziquantel
was released in 1979, but was never studied in pregnant or lactating women and remains a United States
Federal Drug Administration pregnancy Class B drug due to lack of well controlled trials during human
pregnancy. This talk will address results of a randomized controlled trial of praziquantel given to pregnant
women with S. japonicum infection in Leyte, The Philippines. A discussion of next steps to increase the
number of women treated will be presented.
Session 2a. Frontiers in Infectious Diseases
Friday, 9:15 – 11:30 a.m.
GEC Auditorium
Congenital zika virus infections in macaque monkeys
DAVID O’CONNOR, University of Wisconsin, Madison, Wisconsin
The emergence of Zika virus in the Americas and its association with congenital abnormalities motivated
researchers from around the world to study this enigmatic and previously ignored pathogen. This presentation
will overview what has been learned studying Zika virus in nonhuman primates and will identify major
research questions whose answers are still elusive.
Using science to defeat malaria in sub-Saharan Africa
MIRIAM LAUFER, University of Maryland School of Medicine, Baltimore, Maryland
While there has been great progress in malaria control even in the hardest hit countries, malaria continues to
kill one child every minute in sub-Saharan Africa. Dr. Laufer has spent her career investigating how malaria
spreads and causes disease with the goal of introducing innovative interventions that will have long-lasting
impact. This presentation will address several of the key challenges to malaria control and elimination in subSaharan Africa: infant susceptibility to infection, HIV-malaria interactions and silent reservoirs of malaria
transmission in school-age children.
Session 2b. 2017 John H. Erskine Lecturer in Infectious Diseases
Friday, 11:30 a.m. – 12:30 p.m.
GEC Auditorium
Understanding measles in the 21st century
DIANE GRIFFIN, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
Measles remains an important cause of morbidity and mortality worldwide despite the availability of a
safe and efficacious vaccine. Progress has been made in understanding the pathogenesis of measles
virus infection with recognition that virus clearance is a prolonged process. During clearance there is
both immune suppression and continued maturation of the measles virus-specific immune response
likely responsible for establishing life-long immunity. To prevent outbreaks, high population immunity
is needed and requires delivery of 2 doses of vaccine. Failure of measles virus control is due to
difficulties with delivery in developing countries and resistance to vaccination in developed countries.
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 4
Session 3. Oral Presentations by PIDS and PIDS-St. Jude Fellows and Meeting Attendees
Friday, 1:30 – 4:00 p.m.
GEC Auditorium
Clinical and molecular evidence to support school-based mass treatment of malaria
Lauren Cohee, University of Maryland School of Medicine, Baltimore, Maryland
Malaria remains a significant cause of morbidity and mortality worldwide. Current malaria control
interventions primarily focus on prevention and treatment in those at highest risk of disease: children under
five years of age and pregnant women. However, individuals who are infected but at lower risk of disease also
contribute to the transmission of malaria. School-age children in Malawi have a high prevalence of subclinical P. falciparum infections and many of their infections contain gametocytes, the parasite stage required
for transmission to the mosquito. School-based cohort studies in Malawi show that treatment for malaria in
school age children improves their health and may decrease transmission in the community.
Regulation of IFN and cytosolic DNA responses by autophagy
ANTHONY ORVEDAHL, Washington University School of Medicine, St. Louis, Missouri
Mice lacking genes for autophagy, a cell-intrinsic cytoplasmic recycling pathway, leads to inflammation due
to an unknown trigger. We are investigating the role of autophagy in IFN responses using transcriptomics and
CRISPR screening. To evaluate the role of endogenous retroelements as a potential inflammatory trigger we
have developed an RNA-seq transcriptomics pipeline. The intersection of autophagy, IFN, and endogenous
retroelements will be discussed.
One size does not fit all: evaluating decision support tools for resource limited settings
SHEENA MUKKADA, St. Jude Children’s Research Hospital, Memphis, Tennessee
In low- and middle-income countries (LMICs), inconsistent management of infectious complications is a
major contributor to treatment related mortality among pediatric oncology patients. Practice standardization
through the use of clinical decision-support tools has been incompletely studied in settings with limited
resources. Targeting the oncologic emergency of fever, we identify barriers at the patient, provider and
institutional levels that demand adaptations to conventional management algorithms designed for highincome country settings. We also illustrate that monitoring adherence identifies priorities for improvement of
care and resource utilization in LMIC.
Differentiating zika and dengue virus infections with a linear peptide array
EMMA MOHR, University of Wisconsin, Madison, Wisconsin
Identifying women at risk of congenital Zika virus transmission is complicated by the lack of sensitive,
specific, and scalable diagnostic tools. Conventional serologic assays, which are necessary to identify at-risk
pregnancies in women who have already cleared viremia, cannot distinguish between Zika virus and closely
related flaviviruses such as Dengue virus that are co-endemic. In order to develop Zika virus-specific
serologic assays, ZIKV-specific epitopes that do not cross react with Dengue-specific epitopes must be
identified. We utilized rhesus macaque serum from pre-ZIKV challenge, post-primary ZIKV challenge and
post-secondary ZIKV challenge timepoints to identify linear B-cell epitopes unique to Zika virus. We
designed a high density peptide array containing peptides representing a library of multiple Flavivirus
polyproteins and measured the reactivity of pre-Zika challenge and post-Zika challenge rhesus macaque sera
to the peptides. We identified two linear epitopes in the ZIKV envelope glycoprotein region that demonstrate
reactivity with post-ZIKV challenge sera in three animals challenged with Asian lineage ZIKV at both the
post-primary challenge and post-rechallenge timepoints. The pre-ZIKV challenge sera from these animals did
not react with these linear peptides. Importantly, this ZIKV-immune sera did not cross react with the
corresponding peptides in the envelope glycoprotein of Dengue serotypes 1, 2, 3 or 4. These unique linear
epitopes may be utilized to develop diagnostic serologic assays for Zika virus infection.
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 5
IFN-α induces RSV-specific IgA production in neonatal mice after RSV infection
DIEGO HIJANO, St. Jude Children’s Research Hospital, Memphis, Tennessee
RSV is the leading viral respiratory pathogen in infants. Mucosal RSV vaccines have the potential to reduce
RSV disease burden through herd immunity. Adult host response to vaccination often appears to center on
early activation of innate, type 1 interferon dominated pathways (e.g. IFN- α), followed by pathways involved
in B cell maturation that leads to antibody production. For both pathways, substantial age-dependent
differences appear to exist. Little is known about the mucosal immune response capabilities at young ages.
Five-day-old pups (neonates) or 6-8 week-old adults were infected intranasally (in) with RSV. Additionally, a
group of five-day-old pups received IFN-α (in) prior to RSV infection. IgA was measured from nasal washes
collected at different time points. Nasal associated lymphoid tissue (NALT) and lungs were stained by
immunohistochemistry (IHC) for B cells, B cell activating factor (BAFF), and IgA.
Adults infected with RSV had significantly more BAFF and IgA in NALT when compared to neonates upon
primary infection. Neonates that received IFN- α prior to RSV infection had significantly higher levels of
RSV specific IgA in nasal wash when compared to neonates that received vehicle control. Furthermore, RSV
specific IgA levels in IFN-α treated neonates at 14 and 21 days post infection were similar to that of adult
mice infected with RSV. Interestingly, upon reinfection neonatal mice that received IFN- α when compared to
those who did not, had more IgA in lungs by IHC as early as 7 days post infection.
B cell responses and IgA production are attenuated in neonates in response to RSV infection. IFN-α
supplementation of neonates at the time of RSV infection induces IgA production to levels observed in adult
mice during primary infection. Taken together, these data suggest that age differences in type 1 interferon
dominated pathways are critical for antibody production during RSV infections.
Investigation of viral virulence determinants of invasive neonatal HSV disease
LISA AKHTAR, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Neonates infected with herpes simplex virus (HSV) at the time of birth have different clinical courses. The
majority display infection of only the skin, eyes, or mouth (SEM disease). However, others develop invasive
systemic (disseminated) or central nervous system (CNS) infections associated with significant morbidity and
mortality. The factors that predispose a neonate to invasive HSV infection are not known. The goal of this
study is to assess the contribution of variations within the viral genome to the observed clinical phenotype,
and to identify viral virulence determinants of invasive disease. We obtained twelve HSV-2 isolates cultured
from neonates with SEM, disseminated, or CNS disease. Viruses were minimally passaged and their complete
viral DNA genomes were sequenced. This represents the largest group of neonatal HSV genomes sequenced
to date. Isolates were characterized extensively in vitro with the number of plaque forming units produced
(titer), number of genome copies produced, ratio of genome copies to overall titer, plaque size, and plaque
morphology determined for each HSV isolate. Plaque size showed notable interstrain differences, with larger
plaques more likely to have originated from neonates with invasive disease. Ongoing work aims to compare
the consensus genome sequences of each HSV-2 isolate, and to identify nonsynonymous variations that
segregate with clinical disease phenotypes and meaningful in vitro characteristics. This study represents the
first-ever application of comparative pathogen genomics to neonatal HSV disease.
Gut microbiome predicts infectious complications in children with acute lymphoblastic leukemia
HANA HAKIM, St. Jude Children’s Research Hospital, Memphis, Tennessee
Background: The gut microbial colonization in children with acute lymphoblastic leukemia (ALL) plays an
important role in development of infections during chemotherapy.
Methods: Children were enrolled at ALL diagnosis between 2012 and 2015. Stool specimens were collected
before and after initiation of chemotherapy. The bacterial 16S gene was analyzed to obtain diversity and
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 6
composition of microbiome. Enteric viruses were detected using quantitative real-time PCR. Medical records
were reviewed for development of febrile neutropenia (FN) over 6 months after ALL diagnosis, and for
Clostridium difficile infections and antibiotic prophylaxis during induction.
Results: Analysis included 361 stool samples from 187 patients. Shannon diversity index significantly
decreased after induction chemotherapy. The richness of the gut with commensal bacterial taxa significantly
decreased while that of pathogenic bacteria increased after chemotherapy. Multivariate analysis adjusting for
race, gender, age, and ALL risk classification showed that only the abundances of Clostridiaceae and
Proteobacteria before initiation of chemotherapy were independent predictors for subsequent FN episodes.
Compared to no prophylaxis or other prophylaxis, levofloxacin eliminated the risk of Clostridium difficile
infection during induction chemotherapy. Percent of stool specimens with detected enteric viruses increased
after initiation of chemotherapy. Using next-generation sequencing of the gut virome, Astrovirus, other
human viruses and bacteriophage were detected in stool specimens with widespread diversity between
patients.
Conclusions: Gut microbiome and enteric viruses change during chemotherapy for children with ALL.
Richness of gut microbiome with Clostridiaceae and Proteobacteria, but not diversity, before initiation of
chemotherapy predicted subsequent FN episodes. Microbiome analysis may serve to stratify risk of infection.
Germinating spores as precursors of quiescent cryptococcal infection in the zebrafish
J. MUSE DAVIS, University of Wisconsin, Madison, Wisconsin
Cryptococcal meningitis is a devastating invasive fungal disease of the brain, seen in over one million patients
each year and killing ~600,000. Although it most often strikes immunocompromised hosts, people with no
immune deficiency can also be affected. Infection occurs in the lungs, usually without symptoms, and
meningitis may not appear for years. In urban settings seropositivity for Cryptococcus is greater than 60% in
10 year old children, despite the fact that clinical disease is extremely rare in the pediatric population. Thus,
many future victims of cryptococcal meningitis now carry the fungus in a dormant state. Understanding how
the host and fungus develop this quiescent relationship is a critical first step in determining which individuals
are most at risk for disease and what can be done to prevent it.
Cryptococcus exists in the environment in association with trees, soil, and bird droppings. Studies using mice
have shown that both yeast and spores can establish lung infections and cause meningitis. It is unknown
whether human infection is initiated by spores, yeast, or both. Using a model of cryptococcal infection using
the zebrafish larva, we have demonstrated that, as in mice, both spores and yeast can cause disseminated
disease in zebrafish larvae, including meningitis. One unique property of spores in this model is the ability, at
low inoculae, to establish a prolonged, non-progressive infection, in which germinated spores persist within
tissue macrophages but do not replicate. We propose this state as a possible precursor to long-term latency.
In parallel experiments in vitro, we find evidence for a distinct stage of germination with yeast morphology
but without vegetative growth. By combining these in vitro studies of the regulation of germination with in
vivo observations of host-cryptococcal interactions, we propose a timeline of events that parallel the early
establishment of latent infection.
Session 4. Poster Session
Friday, 4:15 – 5:15 p.m.
GEC Foyer
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 7
Session 5. Luminary in Pediatric Infectious Diseases
Saturday, 8:00 – 8:45 a.m.
GEC Auditorium
Pertussis vaccines: opportunities & challenges
KATHRYN M. EDWARDS, University of Vanderbilt
Prominent local and systemic reactions to whole cell pertussis vaccines in the early 1980s resulted in
declining vaccination rates with outbreaks occurring in a number of countries. In the United States
litigation associated with these reactions forced several manufacturers to cease producing whole cell
pertussis vaccines and increasing numbers of parents were fearful of this vaccine. This concern
stimulated research on the biology of the pertussis organism and the generation of new vaccines
containing one or more purified pertussis antigens. These “acellular vaccines” were extensively
tested and found to be less reactive, immunogenic and efficacious for the prevention of pertussis
disease. They were soon licensed in many of the developed countries and totally replaced the whole
cell vaccines. However, in the past decade the acellular vaccines have been associated with
outbreaks, suspected to be due to waning immunity. The outbreaks have also been associated with
the deaths of infants too young to be immunized. Maternal immunization programs have been shown
to be effective in reducing the burden of infant pertussis and have been recommended for each
pregnancy in the United States.
Studies of the memory responses to whole cell and acellular vaccines and nonhuman primate models
of pertussis have elucidated some reasons why the acellular vaccines are associated with waning
immunity. Memory responses seen after whole cell pertussis vaccine priming reflect better long
term protection against pertussis disease. Although acellular vaccines generate higher levels of
antigen specific IgG to the antigens included in the acellular pertussis vaccines, there are many more
pertussis antigens included in whole cell vaccines. In addition, acellular pertussis vaccine priming is
associated with skewing of the immune response to a more Th2 like response, while whole cell
priming is associated with a Th1/Th17 response. Repeated booster doses of acellular vaccine in
children primed with acellular vaccine have also been shown to result in progressively shorter
duration of protection against disease. This may be explained by the generation of higher levels of
antigen specific IgG4, which does not bind complement and leads to a suboptimal inflammatory
response and impaired phagocytosis and antimicrobial defense. In contrast, whole cell priming
followed by acellular pertussis vaccine boosting results in better opsonization, phagocytosis, and
complement mediated killing through the preferential induction of IgG1. How the acellular vaccines
can be made more immunogenic and can be programmed to generate a more Th1/Th17 response will
be discussed. The study of pertussis vaccines over the past 40 years has been a challenging endeavor
and one that continues to evolve.
Session 6. Frontiers in Infectious Diseases Pt. 2
Saturday, 8:45 – 10:15 a.m.
GEC Auditorium
Change the world: 16 years of molecular, translational, and clinical advances against fungi and where
we are going now
WILLIAM STEINBACH, Duke University, Durham, North Carolina
With continued medical advances and an expanding immunosuppressed patient population, there is an everincreasing importance placed on the most deadly of infections in immunocompromised hosts – invasive
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 8
fungal infections. Dr. Steinbach will go over the advances his laboratory has made in understanding the
molecular basis for invasive aspergillosis, and also how (with the multi-national collaboration) they are
developing new insights into pediatric invasive fungal disease epidemiology, diagnosis, and treatment.
The human microbiome during pregnancy and its possible role in premature labor
DAVID A. RELMAN, Stanford University, Palo Alto, California
The human indigenous microbial communities (microbiota) play critical roles in health and may be especially
important for mother and fetus during pregnancy. In previous work, based on a case-control study of 49
women—including 15 of whom delivered preterm, we characterized weekly variation in the vaginal, gut and
oral microbiota during and after pregnancy. Of note, an altered vaginal microbial community early in
pregnancy was associated with subsequent preterm birth. In addition, we discovered an abrupt change in the
vaginal microbiota at delivery that persisted in some cases for at least one year. These and more recent
findings of ours suggest that pregnancy outcomes might be predicted by features of the microbiota early in
gestation, and reinforce the concept that the microbiota helps to shape the gestational environment of the
developing fetus with potential long-term consequences for child health.
Session 7. Career Development Presentation
Saturday, 10:30 –11:15 a.m.
GEC Auditorium
Mentorship: thriving in your mentor/trainee relationship
KATHRYN M. EDWARDS, Vanderbilt University, Nashville, Tennessee
Productive mentoring relationships markedly enhance the academic careers of both the mentee and the
mentor. However, for these relationships to be successful they must include several aspects. First there must
be reciprocity in the relationship with both individuals benefitting from the interactions. Second, there must
be mutual respect with both individuals working together to attain the goals of the research. Third, there must
be clear expectations for both the mentor and the mentee that are outlined at the onset of the relationship and
both must be accountable for meeting the projected goals. Finally, these should be a personal connection
between the mentee and mentee where you have shared values and a common ground. How to achieve and
sustain these productive mentorship relationships will be discussed.
Session 8. Career Pathways Brief Talks/Panel Discussion
Saturday, 11:15 a.m. – 12:30 p.m.
GEC Auditorium
The career pathways session will bring together several faculty members with differing career paths. Each
panelist will provide a short talk that introduces the audience to their field and touch on the pros/cons of this
career option. After all panelists have given their short talk, they will join each other on stage and answer
questions related to career development. There will be a few facilitated questions, but the majority of the
discussion will be driven by attendees’ questions.
Session 9. Career Paths Breakout Discussions
Saturday, 12:15 – 1:45 p.m.
GEC Conference Rooms
K Awards/Loan Repayment Program
In this session, faculty will discuss the structure and requirements of the NIH’s K series awards (Career
Development), as well as the Loan Repayment Program. In addition, Drs. James and Snowden will provide
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 9
advice on avoiding specific application pitfalls, tips for highlighting the strengths of your application and
answer questions from participants on both programs.
Staying academic in a clinically-based career
Are you interested in a career as a clinician educator? This talk will provide an overview of different
opportunities available to educators and those who aspire to be educators. Dr. Myers will also focus on the top
5 things learned so far in her career as an educator.
Mock study section for grant review
In this session, faculty will create an environment that simulates a typical study section, including general
approach to reading grants, ways to avoid specific grant pitfalls, and the importance of a clear presentation of
your proposed work.
Session 10. Research in the Global Health Setting
Saturday, 2:00 – 4:00 p.m.
GEC Conference Rooms
Point of care clinical decision: resources and opportunities for developing countries
CHARLES RUSSELL, St. Jude Children’s Research Hospital
Respiratory virus transmission, disease, and treatment: perspectives from the basic scientist collaborator
Respiratory viruses are a leading cause of illness worldwide and exert a greater burden on public health in
developing countries. Clinical care decision-making and medical advances can benefit by partnerships
between point-of-care physicians and basic scientists. This presentation will highlight various partnership
models from the point-of-view of the collaborating basic scientist. Joint interests in such partnerships may
include pathogen surveillance, determination of mechanisms of pathogen spread and emergence, and
modeling clinical disease symptoms in animal models to both understand and develop new preventative and
therapeutic strategies.
Global Research Panel Discussion
Applying for grants and finding funding for global research projects
STEPHEN WHITE, St. Jude Children’s Research Hospital
HASSAN ZARAKET, American University of Beirut
JOHN P. DEVINCENZO, University of Tennessee Center for Health Sciences
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 10
Poster Presentations
Friday, 4:15 – 5:15 p.m.
GEC Foyer
#1
A novel antibody assay strongly predicts children with S. aureus musculoskeletal infections
#2
Adherence to guidelines for the care of children with cancer and high-risk febrile neutropenia
#3
Assessing the impact of incorporating the CDC bloodstream infection surveillance protocol on infection rates among
pediatric cancer patients in Mexico City
#4
Association between asymptomatic maternal malaria infections and birth weight in Myanmar
#5
Bacteria involved in bloodstream infections in pediatric hematological patients in Lima, Peru
#6
Burden of central-line associated bloodstream infections at a pediatric cancer center in El Salvador
#7
Candida infection of a limb-sparing prosthesis in a teenager with osteosarcoma
#8
Characteristics and outcomes of fungal infections in patients with cancer at a hospital in
Mexico
#9
Characterization of astrovirus-associated gastroenteritis in hospitalized children <5 in Lebanon
#10
Characterization
Argentina
#11
Complication and clinical outcomes of using PICC lines in pediatric oncology patients
#12
Detection of OXA-48 in Klebsiella oxytoca: an unusual finding
#14
Effectiveness of parent education to decrease HAP at a pediatric cardiology unit in Mexico
#15
Enteric fever with S. typhii progressing to hemophagocytic lymphohistiocytosis: a case report
#16
Epidemiology of healthcare-associated infections in patients with cancer in San Pedro Sula, Honduras
#17
Etiology of bacteremia and antimicrobial resistance in pediatric patients with malignancy in Ecuador
#18
Etiology of primary bloodstream infections among children with cancer at a hospital in Guatemala
#19
Follow-up of pediatric patients presenting for “Rule out Sexual Assault” placed on nPEP for HIV
#24
Healthcare-associated bloodstream infections in a pediatric cancer unit in Honduras
#25
How quickly do human viral-induced inflammatory responses resolve after viral replication ceases?
#28
Lymphadenitis-first and facial nerve palsy in an older child: unusual presentations of Kawasaki's
#29
Nasopharyngeal colonization with non-typable H. influenzae: innate immunity and disease severity
of
respiratory
viral
infections
in
children
with
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 11
cancer
in
posadas,
#30
Penicillin resistance identified in a case of thoracic actinomycosis
#31
Predictive value of birth dose of hepatitis B Vaccine on vaccination status at 18 months
#32
Pro-inflammatory mediators may distinguish infection from trauma in a rat model of shunt infection
#33
Propagation of astrovirus VA1, a recently identified neurotropic human astrovirus, in cell culture
#34
Respiratory virus infection characteristics among children with cancer in Lebanon
#35
Surveillance for influenza C infection, Minnesota, 2013-2016
#36
Towards a collaborative, e-learning approach for disseminating infection prevention policies
#37
Treatment of neonatal chlamydial conjunctivitis: a systematic review and meta-analysis
#38
Trends in the clinical course of pediatric fatalities to visceral leishmaniasis in Teresina, Brazil
#39
Uncommon cases of bacterial meningitis in children
#40
Viral respiratory panel (VRP) testing in a Tertiary neonatal intensive care unit (NICU)
#41
Intraventricular amikacin in MDR Klebsiella pneumonia shunt-associated ventriculitis
#42
Rothia mucilaginosa infections in immunocompromised pediatric patients
#43
Characteristics of coronavirus infection in immunocompromised vs. non-immunocompromised
children
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 12
Attendee Listing
Abbasi, Khurshid, MBBS, PhD
Consultant Pediatrician
[email protected]
Baker, Amira, MD
University of California, Los Angeles
[email protected]
Abou-El-Hassan, Hadi, BSc
American University of Beirut
[email protected]
Barmer, Karen, BS
St. Jude Children’s Research Hospital
[email protected]
Acker, Karen, MD
Columbia University - New York Presbyterian
[email protected]
Baviskar, Prady, DVM, PhD
St. Jude Children's Research Hospital
[email protected]
Adderson, Elisabeth, MD
St. Jude Children's Research Hospital
[email protected]
Beneri, Christy, DO
Stony Brook Children's Hospital
[email protected]
Akhtar, Lisa, MD, PhD
Children's Hospital of Philadelphia
[email protected]
Bhalodi, Amira, PharmD
Allergan
[email protected]
Al Hammoud, Roukaya, MD
University of Texas Health-McGovern Medical
School
[email protected]
Bloch, Deborah, MD
Emory University
[email protected]
Alawdah, Laila, MBBS
Boston Children's Hospital
[email protected]
Aldrich, Aileen, MD
University of Nebraska Medical Center
[email protected]
Andrews, Shannon, MD
University of Minnesota
[email protected]
Arias de la Garza, Eduardo, Pediatric
Infectology
Instituto Nacional de Pediatria
[email protected]
Bagga, Bindiya, MD
University of Tennessee Health Sciences Center
[email protected]
Bluestone, Hira, PA-C
Seattle Children's Hospital
[email protected]
Bullington, Craig, BE
UTHSC
[email protected]
Busby, Kenneth, BS
Edward Via College of Osteopathic Medicine
[email protected]
Carrillo, Fanny, Pediatrician
Hospital Nacional de Niños Benjamin Bloom
[email protected]
Cassat, Jim, MD, PhD
Vanderbilt University Medical Center
[email protected]
Chang, Alicia, MD
UNOP
[email protected]
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 13
Attendee Listing
Chang, Yeh-Chung, MD
Children's Hospital of Philadelphia
[email protected]
Englund, Janet, MD
Seattle Children's Hospital
[email protected]
Chuang, Ming Jung, MD
St. Jude Children's Research Hospital
[email protected]
Erickson, Kelley, MSN
Children's Hospital of Philadelphia
[email protected]
Clark, Tammy, RN, BSN
Sanofi
[email protected]
Escobedo, Griselda, PhD, MD
Hospital Civil de Guadalajara
[email protected]
Cortez, Valerie, PhD
St. Jude Children's Research Hospital
[email protected]
Espinoza, Darrell, MD
La mascota Nicaragua
[email protected]
Cross, Shane, PharmD
St. Jude Children's Research Hospital
[email protected]
Essner, Kasie, PharmD, BCPS
Saint Francis Medical Center
[email protected]
Darling, Victoria, BS
St. Jude Children's Research Hospital
[email protected]
Flynn, Pat, MD
St. Jude Children's Research Hospital
[email protected]
Davis, Muse, MD, PhD
University of Wisconsin
[email protected]
Forrest, Heather, DVM
St. Jude Children's Research Hospital
[email protected]
Del Valle Mojica, Coralee, MD, MPH
Lucile Packard Children's Hospital, Stanford
[email protected]
Friedman, Jennifer, MD, PhD
Center for International Health Research and
Alpert Medical School of Brown University
[email protected]
Denison, Mark, MD
Vanderbilt University Medical Center
[email protected]
Dixit, Avika, MBBS MPH
Boston Children's Hospital
[email protected]
Edwards, Kathryn, MD
Vanderbilt University School of Medicine
[email protected]
Emslie, Tami, Bachelor's
UC Davis Medical Center
[email protected]
Garbini, Cecilia, MD
Hospital nacional Alejandro Posadas
[email protected]
Garcia-Maurino, Cristina, MD
Nationwide Children's Hospital
Cristina.Garcia­
[email protected]
Gavigan, Patrick, MD
St. Jude Children's Research Hospital
[email protected]
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 14
Attendee Listing
Gomez, Sergio, MD
Hospital De Niños
[email protected]
Hobbs, Athena, PharmD
Baptist Memorial Hospital-Memphis
[email protected]
Gonzalez, Miriam, MD
St. Jude Children's Research Hospital
[email protected]
Homsi, Maysam, MPH
St. Jude Children's Research Hospital
[email protected]
Habbal, Sarah, MD
St. Jude Children's Research Hospital
[email protected]
Hong, David, MD
Karius, Inc
[email protected]
Haffey, Margaret, MSW
Boston Medical Center
[email protected]
hutto, cecelia, MD
UAB School of Medicine, Department of
Pediatrics
[email protected]
Halasa, Natasha, MD, MPH
VUMC (Vanderbilt)
[email protected]
Hamdy, Rana, MD, MPH
Children's National Health System
[email protected]
Hassouneh, Linda, MD
University of Texass Southwestern
MedicalCenter
[email protected]
Hazleton, Joy, MD, PhD
Children's Hospital Colorado/University of
Colorado School of Medicine
[email protected]
Helgeson, Matthew, PharmD
Theravance Biopharma
[email protected]
Hernandez Orozco, Hilda Gpe, MSc
National Pediatric Institute
[email protected]
Hijano, Diego, MD
St. Jude Children's Research Hospital
[email protected]
Ippagunta, Sirish Kumar, PhD
St. Jude Children's Research Hospital
[email protected]
Janowski, Andrew, MD
Washington University School of Medicine
[email protected]
Jones, Lillian, MS, CCRP
St. Jude Children's Research Hospital
[email protected]
Kanthula, Ruth, MD, MPH
University of Washington
[email protected]
Karandikar, Manjiree, MD, MBS
Boston Children's Hospital
[email protected]
Keaton, Amelia, MD
Children's Hospital of Philadelphia
[email protected]
Kietzman, Colin, PhD
St. Jude Children's Research Hospital
[email protected]
Kirby, Jeannette, MPH
St. Jude Children's Research Hospital
[email protected]
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 15
Attendee Listing
Kitt, Eimear, MB, BCh, BAO(NUI)
The Children's Hospital of Philadelphia
[email protected]
Medzihradsky, Oliver, MD, MPH, MS
University of California San Francisco
[email protected]
Kumar, Madan, DO
Children's National Medical Center
[email protected]
Melgar, Mario, MD
UNOP
[email protected]
La Via, William, MD
[email protected]
Mohr, Emma, MD, PhD
University of Wisconsin-Madison
[email protected]
Lanata, Mariana, MD
Nationwide Children's Hospital
[email protected]
Morley, Sharon Celeste, MD, PhD
Washington University School of Medicine
[email protected]
Laufer, Miriam, MD, MPH
Institute for Global Health, University of
Maryland School of Medicine
[email protected]
Mostafa, Heba, MD, PhD
St. Jude Children's Research Hospital
[email protected]
Li, Ying, MD
St. Jude Children's Research Hospital
[email protected]
Myers, Angela, MD, MPH
Children's Mercy Hospital
[email protected]
Loera, Adriana, MD
Hospital General Tijuana
[email protected]
Nava, Alejandra, MD
Hospital de Especialidades Pediatricas
[email protected]
Lugo, Debra, MD
Mattel Children's Hospital UCLA
[email protected]
O'Brien, Brigid, DO
Tulane University
[email protected]
Madigan, Theresa, MD
Mayo Clinic
[email protected]
Obringer, Emily, MD
University of Chicago Comer Children's
Hospital
[email protected]
Margolis, Ellie, MD PhD
Seattle Children's Hospital
[email protected]
Max, Anita, FNP
St. Jude Children's Research Hospital
[email protected]
McHenry, Megan, MD
Indiana University School of Medicine
[email protected]
Odegbami, Bukola, Doctor
Lagos University Teaching Hospital
[email protected]
Ogimi, Chikara, MD
Seattle Children's Hospital
[email protected]
Olarubofin, Tokunbo, MBBS (Doctor)
Lagos University Teaching Hospital
[email protected]
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 16
Attendee Listing
Ordonez, Sara, MD
Hospital Escuela Universitario Honduras
[email protected]
Ristagno, Elizabeth, MD
University of Louisville School of Medicine
[email protected]
Ouellette, Christopher, MD
Nationwide Children's Hospital
[email protected]
Rodriguez, Juan Pablo, Pediatrician
Infectologist
Hospital del Niño Dr. Ovidio Aliaga Uria
[email protected]
Owens, Christina, CPhT, CCRP
St. Jude Children's Research Hospital
[email protected]
Paulsen, Grant, MD
Cincinnati Children's Hospital
[email protected]
Penkert, Rhiannon, PhD
St. Jude Children's Research Hospital
[email protected]
Pitkin, Julia, BS
Vanderbilt University School of Medicine
[email protected]
Poole, Claudette, MD
University of Alabama, Birmingham
[email protected]
Purandare, Amol, MD
Children's National Medical Center
[email protected]
Raabe, Vanessa, MD, MSc
Emory University
[email protected]
Ramirez, Moises, Doctor
Intituto Nacional de Pediatria
[email protected]
Rathore, Mobeen, MD
University of Florida / UF Health
[email protected]
Richardson, Katherine, MD
Children's Mercy Hospital Kansas City
[email protected]
Romero Reyes, Luis, MD
Hospital Mario Catarino Rivas
[email protected]
Russo, Michael, MD
Children's Hospital of Philadelphia
[email protected]
Saccoccio, Frances, MD, PhD
Duke University Hospital
[email protected]
Sato, Alice, MD, PhD
Rocky Mountain Hospital for Children
[email protected]
Scaggs Huang, Felicia, MD
Cincinnati Children's Hospital Medical Center
[email protected]
Schneider, Jack, MD
Indiana School of Medicine
[email protected]
Schultz-Cherry, Stacey, PhD
St. Jude Children's Research Hospital
[email protected]
Sharma, Akshay, MBBS
St. Jude Children's Research Hospital
[email protected]
Sharma, Tanvi, MD, MPH
Boston Children's Hospital
[email protected]
Snowden, Jessica, MD
University of Nebraska Medical Center
[email protected]
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 17
Attendee Listing
Somarriba, Maria, Infectology Pediatric
Hospital Infantil Manuel de Jesus Rivera
[email protected]
Williams, John, MD
Children's Hospital of Pittsburgh
[email protected]
Spearman, Paul, MD
Cincinnati Children's Hospital Medical Center
[email protected]
Wohrley, Julie, MD
University of Chicago, Comer Children's
Hospital
[email protected]
Statler, Victoria, MD
University of Louisville
[email protected]
Stronski, Lauren, BSN
St. Jude Children's Research Hospital
[email protected]
Thielen, Beth, MD, PhD
University of Minnesota
[email protected]
Thomsen, Isaac, MD
Vanderbilt University Medical Center
[email protected]
Tinoco, Ivan, MD
Hospital Materno Infantil de Badajoz
[email protected]
Wolf, Joshua, MBBS
St. Jude Children's Research Hospital
[email protected]
Xu, Corey, PhD
St. Jude Children's Research Hospital
[email protected]
Xu, Peng, PhD
St. Jude Children's Research Hospital
[email protected]
Yeganeh, Nava, MD
UCLA
[email protected]
Zaidi, Hina, MD
Stony Brook Children's Hospital
[email protected]
Tribble, Alison, MD
C.S. Mott Children's Hospital, University of
Michigan
[email protected]
Zaramella, Renan, MD
St. Jude Children's Research Hospital
[email protected]
Tuomanen, Elaine, MD
St. Jude Children's Research Hospital
[email protected]
Zhu, Frank, MD
Children's Hospital of Michigan
[email protected]
Vora, Surabhi, MD, MPH
Seattle Children's Hospital
[email protected]
Zuber, Janie, MD
University of Maryland
[email protected]
Waddell, Joel, DO
Children's Mercy Hospital
[email protected]
Weinberg, Jason, Pediatrics
University of Michigan
[email protected]
St. Jude/PIDS Pediatric Infectious Diseases Research Conference
Page 18
:Notes St. Jude/PIDS Pediatric Infectious Diseases Research Conference
:Notes St. Jude/PIDS Pediatric Infectious Diseases Research Conference
:Notes St. Jude/PIDS Pediatric Infectious Diseases Research Conference
:Notes St. Jude/PIDS Pediatric Infectious Diseases Research Conference
•
Entrance Gate (1-5)
~
Patient Only Parking
Marlo Thomas Center
Kay Kafe
Mail Room
~
Dock (1-7)
@
@
©
@
®
®
@
®
CD
Danny Thomas/ALSAC Pavilion
Patient Care Center
Richard C. Shadyac ALSAC Tower
Danny Thomas Research Center
Integrated Research Center
Central Energy Plant
AutoZone Garage 1
Incinerator/Hazardous Waste
Chili's Care Center
®
Q)
®
©
~
®
@
(@
®
Kay Research & Care Center
545 Danny Thomas Place
595 Building
567 Danny Thomas Place
505 Building
305 Building
Tamer-Rashid (ALSAC HQ)
Domino's Event Center
AutoZone Garage 2
@
®
®
©
@
@
@)
®
®
Kmart St. Jude Life Center
Longinotti Building
Barry Building
Tri Delta Place
ALSAC Gift Shop
St. Jude GMP Facility
448 North Second
160 Shadyac Avenue
Garage 3